Fresenius and SAP Plan Strategic Partnership to Advance Sovereign and AI-Driven Digital Healthcare

(IN BRIEF) Fresenius and SAP have announced plans to form a strategic partnership to accelerate digital innovation in healthcare and establish a sovereign, interoperable, and AI-supported healthcare ecosystem. By combining Fresenius’ global healthcare expertise with SAP’s digital platforms and AI technologies, the companies aim to create a secure, data-driven backbone for hospitals and medical facilities worldwide. Built on SAP’s core enterprise and data technologies and aligned with open standards such as HL7 FHIR, the initiative supports data sovereignty, regulatory compliance, and seamless system integration. Backed by a planned mid three-digit million euro investment, the partnership seeks to improve efficiency, transparency, and quality across the healthcare value chain while advancing digital transformation across Germany and Europe.

(PRESS RELEASE) BAD HOMBURG, 19-Jan-2026 — /EuropaWire/ — Fresenius and SAP have announced plans to enter into a strategic partnership aimed at accelerating innovation in digital healthcare delivery and strengthening the foundations of a sovereign, interoperable, and AI-enabled healthcare system. The collaboration brings together Fresenius’ global healthcare expertise with SAP’s advanced digital and AI technologies to establish a secure, data-driven ecosystem designed to support hospitals and medical facilities worldwide.

The planned partnership focuses on building a scalable digital backbone for healthcare that meets stringent requirements for data sovereignty, security, and regulatory compliance. By combining clinical know-how with enterprise-grade digital platforms, Fresenius and SAP intend to enable the responsible use of health data and the secure deployment of AI across healthcare operations, supporting improved outcomes and operational efficiency across the entire care continuum.

At the core of the initiative is the joint development of an individual, modular healthcare platform that enables connected and data-driven processes. The platform will be built on established SAP technologies, including SAP Business Suite, SAP Business Data Cloud, SAP Business Technology Platform, and SAP Business AI. These technologies will provide a unified, compliant, and expandable foundation for secure data exchange, controlled AI model operation, and interoperable system integration.

A central element of the collaboration is the ambition to create a sovereign European healthcare solution that supports modern hospital information systems in line with SAP’s AnyEMR strategy. Open industry standards such as HL7 FHIR will be used to enable seamless integration between hospital information systems, electronic medical records, and other clinical applications, helping healthcare providers modernize their digital infrastructures while maintaining control over sensitive data.

The partnership also includes plans for a significant medium-term investment in the mid three-digit million euro range to advance digital and AI-supported healthcare solutions across Germany and Europe. Implementation will be supported through multiple forms of collaboration, including joint investments in startups and scaleups, co-development of new technologies, and coordinated governance structures to ensure alignment between both organizations.

Through this strategic partnership, Fresenius and SAP aim to set new benchmarks for digital sovereignty, security, and innovation in healthcare, while enabling clinicians and hospital teams to integrate AI and data-driven processes into everyday practice and focus more fully on patient care.

Media Contact:

Steffen Rinas
T +49 (0) 6172 608-6698
steffen.rinas@fresenius.com

Dana Roesiger, +49 62277 7 63900, dana.roesiger@sap.com, CET
SAP Press Room; press@sap.com

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

SOURCE: Fresenius AG